Answers are grounded in this paper and cite their sources.
Phase I/II study demonstrates safety and efficacy of gilteritinib with chemotherapy in FLT3-mutated AML patients, indicating promising therapeutic options.
Background: Mutations in the FMS -like tyrosine kinase 3 ( FLT3 ) gene are present in approximately 30% of patients with newly diagnosed (ND) acute myeloid leukemia (AML), and are associated with worse therapy outcomes compared to the general AML population. Gilteritinib, a selective oral FLT3 inhibitor, is a promising treatment option for this patient population. Objectives: To assess the safety and efficacy of gilteritinib in combination with induction and consolidation chemotherapy in Asian patients with ND, FLT3 -mutated ( FLT3 mut+ ) AML. Design: This study was a phase I/II open-label, single-arm study. Herein, we present the final results from phase II. Methods: A total of 84 patients were enrolled in 33 centers across Japan, Korea, and Taiwan. All patients enrolled in phase II received induction and consolidation therapy with gilteritinib 120 mg/day plus chemotherapy (induction: ⩽2 cycles, idarubicin/cytarabine once-daily; consolidation: ⩽4 cycles, cytarabine twice-daily) followed by maintenance with gilteritinib 120 mg/day monotherapy (⩽26 cycles). The primary efficacy endpoint was the complete remission (CR) rate after induction therapy. Results: The primary endpoint of CR rate after induction was 50.0% (90% CI: 40.4–59.6). Gilteritinib in combination with chemotherapy achieved high composite CR (CRc; 86.6%, 95% CI: 77.3–93.1) rates after induction. The overall survival (OS) rate at 3 years was 71.6%, and the median OS was 48.2 months; however, due to the immaturity of the data, the median OS should be interpreted with caution. In addition, 51.2% of patients underwent hematopoietic stem cell transplantation during the study period. The safety profile of gilteritinib was as expected, and no new safety signals were identified. Conclusion: Induction and consolidation with gilteritinib plus chemotherapy, and maintenance with gilteritinib monotherapy were well tolerated in ND patients in Asia with FLT3 mut+ AML and had favorable efficacy compared with historical data. Trial registration: This trial was registered with the ClinicalTrials.gov identifier NCT02310321.
No takes yet. Share an insight, caveat, or question.
Sawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: